Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 638Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 381Lymphoma 358Melanoma 335Leukemia 335Neoplasm Metastasis 323Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 283Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 196Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 172Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

continuous erythropoietin receptor activator 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has results × Renal Anemia × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡